CRCT News
A small non-coding RNA molecule controls the presence of three key tumor growth regulators of NPM-ALK(+) T lymphoma.
Lymphoma is a blood cancer which develops from a type of white blood cells present in the lymphatic system; the lymphocytes. There are two types of lymphocytes: B lymphocytes and T lymphocytes. This study focuses on a particular type of blood cancer affecting T...
Supramolecular attack particles are autonomous killing entities released from cytotoxic T-cells
Cytotoxic T cells (CTL) are essential cellular components in the immune response against viruses and cancer. This is why it is essential to better understand the function of these cells and in particular to better understand how these cells manage to kill their target...
Role of sphingosin kinase 1 in cancer immunotherapy
Immunotherapy is a treatment that aims to educate our immune system against cancer cells. This treatment resulted in a long-term response in patients with metastatic melanoma (40-60%) with in some cases total tumour regression. The challenge is now that the maximum...
New therapeutic perspectives for dendrogenin A, a cholesterol-derived metabolite
Dendrogenin A (DDA) is a tumor suppressor mammalian cholesterol-derived metabolite and a new class of ligand of the Liver X receptor (LXR), which displays tumor cell differentiation. In human and mouse breast adenocarcinoma cells, DDA-induced cell differentiation was...
LungPredict: improve and personalize immuno-therapies
A collaboration in Toulouse, France, between Pierre Fabre Research Institute, the University Cancer Institute and the Cancer Research Center aims to collect and integrate data to improve and personalize immuno-therapies. Immunotherapies are imposing themselves as a...
Three major stakeholders of the Oncopole form a strategic public-private sector alliance to boost innovation in oncology on the Toulouse campus
A multi-year framework agreement has just been signed by 3 major stakeholders present on the Oncopole campus in Toulouse: the Pierre Fabre Research Institute (IRPF), the Centre de Recherches en Cancérologie de Toulouse (CRCT-Inserm) and the Institut Universitaire du...